Skip to main content

Table 1 Experience with biologics in juvenile dermatomyositis in survey #1 in 2012

From: Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

No experience at all

35 (39%)

Etanercept

5 (5%)

Abatacept

0 (0.0%)

Adalimumab

0 (0.0%)

Infliximab

4 (4%)

Anakinra

1 (1%)

Tocilizumab

0 (0.0%)

Rituximab

29 (32%)

Canakinumab

0 (0%)

Multiple

16 (18%)

Other

1 (1%)